The earnings call highlights several negative factors: reduced revenue guidance, increased dependence on the BARDA contract, rising operating costs, and a net loss increase. Although there are some positive aspects, such as FDA submission progress and positive feedback from international markets, these are overshadowed by the negative financial trends and uncertainties about future revenue and commercialization. The Q&A session further underscores these concerns, with management providing vague responses on critical matters, contributing to a negative sentiment and likely negative stock price reaction.
Report
Attend Webcast
